Predictors of clinical relapse in the USTMA retrospective iTTP cohort
| Variable . | HR . | 95% CI . |
|---|---|---|
| Second or subsequent rituximab course | 2.80 | 1.53-5.10 |
| Relapsed iTTP | 2.10 | 1.24-3.58 |
| Black race | 3.12 | 1.68-5.80 |
| Age: 18-33 y (Q1) | Reference | |
| Age: 33.1-42.2 y (Q2) | 0.55 | 0.30-0.98 |
| Age: 42.4-54.8 y (Q3) | 0.64 | 0.38-1.07 |
| Age: 54.9-81.0 y (Q4) | 0.54 | 0.30-0.95 |
| Female sex | 1.23 | 0.81-1.89 |
| Peak LDH level | 1.67 | 0.86-3.28 |
| Exacerbation present | 1.16 | 0.74-1.82 |
| Variable . | HR . | 95% CI . |
|---|---|---|
| Second or subsequent rituximab course | 2.80 | 1.53-5.10 |
| Relapsed iTTP | 2.10 | 1.24-3.58 |
| Black race | 3.12 | 1.68-5.80 |
| Age: 18-33 y (Q1) | Reference | |
| Age: 33.1-42.2 y (Q2) | 0.55 | 0.30-0.98 |
| Age: 42.4-54.8 y (Q3) | 0.64 | 0.38-1.07 |
| Age: 54.9-81.0 y (Q4) | 0.54 | 0.30-0.95 |
| Female sex | 1.23 | 0.81-1.89 |
| Peak LDH level | 1.67 | 0.86-3.28 |
| Exacerbation present | 1.16 | 0.74-1.82 |
LDH, lactate dehydrogenase; Q, quartile.